Table 2.
SLE treatments during exposure perioda
| Commercially-insured (n = 8,231) | Medicaid-insured (n = 802) | |||
|---|---|---|---|---|
| Moderate/severe SLE (n = 5,551) | Mild SLE (n = 2,680) | Moderate/severe SLE (n = 600) | Mild SLE (n = 202) | |
| Antimalarials | 3,455 (62.2)b,c | 2,106 (78.6)b,c | 304 (50.7)b,c | 74 (36.6)b,c |
| Chloroquine | 28 (0.5) | 9 (0.3) | 4 (0.7) | 1 (0.5) |
| Hydroxychloroquine | 3,429 (61.8)b,c | 2,099 (78.3)b,c | 301 (50.2)b,c | 74 (36.6)b,c |
| Biologic therapies | 113 (2.0)b | 0 (0.0)b | 18 (3.0)d | 0 (0.0)d |
| Abatacept | 29 (0.5)b | 0 (0.0)b | 3 (0.5) | 0 (0.0) |
| Belimumab | 11 (0.2)d | 0 (0.0)d | 2 (0.3) | 0 (0.0) |
| Rituximab | 74 (1.3)b,e | 0 (0.0)b | 14 (2.3) d,e | 0 (0.0)d |
| Immunosuppressants | 2,858 (51.5)b,c | 0 (0.0)b | 235 (39.2)b,c | 0 (0.0)b |
| Azathioprine | 772 (13.9)b,e | 0 (0.0)b | 62 (10.3)b,e | 0 (0.0)b |
| Cyclophosphamide | 101 (1.8)b,e | 0 (0.0)b | 19 (3.2)d,e | 0 (0.0)d |
| Cyclosporine | 61 (1.1)b | 0 (0.0)b | 3 (0.5) | 0 (0.0) |
| IV immunoglobulin | 51 (0.9)b | 0 (0.0)b | 5 (0.8) | 0 (0.0) |
| Leflunomide | 143 (2.6)b,e | 0 (0.0)b | 4 (0.7)e | 0 (0.0) |
| Methotrexate | 904 (16.3)b,c | 0 (0.0)b | 52 (8.7)b,c | 0 (0.0)b |
| Mycophenolate mofetil | 1,052 (19.0)b | 0 (0.0)b | 110 (18.3)b | 0 (0.0)b |
| Tacrolimus | 125 (2.3)b | 0 (0.0)b | 10 (1.7) | 0 (0.0) |
| Systemic glucocorticoids | 4,773 (86.0)b,c | 574 (21.4)b,c | 562 (93.7)b,c | 128 (63.4)b,c |
| Prednisone | 3,481 (62.7)b,c | 380 (14.2)b,c | 450 (75.0)b,c | 94 (46.5)b,c |
| Prednisolone | 13 (0.2)e | 2 (0.1) | 6 (1.0)e | 1 (0.5) |
| Hydrocortisone | 84 (1.5)b | 3 (0.1)b | 15 (2.5)d | 0 (0.0)d |
| Oral methylprednisolone | 765 (13.8)b | 221 (8.2)b,c | 75 (12.5)d | 40 (19.8)c,d |
| IV methylprednisolone | 1,204 (21.7)b,e | 0 (0.0)b | 164 (27.3)b,e | 0 (0.0)b |
| Dexamethasone | 598 (10.8)b,c | 19 (0.7)b | 96 (16.0)b,c | 2 (1.0)b |
Values are N (%) assessed during the first six months following the index date (inclusive of the index date). Statistical comparisons were performed (1) between the two severity groups in each payer group, (2) between the two payers for each severity. Only the differences reaching statistical significance (p<0.05) were displayed using specific superscripts.
p<0.001, moderate/severe versus mild SLE within either the commercially-insured or Medicaid population.
p<0.001, moderate/severe commercially-insured versus moderate/severe Medicaid or mild commercially-insured versus mild Medicaid.
p<0.05, moderate/severe versus mild SLE within either the commercially-insured or Medicaid population.
p<0.05, moderate/severe commercially-insured versus moderate/severe Medicaid.
Abbreviations: IV, intravenous; SLE, systemic lupus erythematosus.